Katerina Roznik
Biotech Blueprint
Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.
Author
Katerina Roznik
Category
Podcast website
Latest episode
May 19, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Install for free
Android 5M+ downloads · 4.8 rating
iOS soon
Episodes
Moderna in 2026: What the Wins and Losses Are Telling Us 19.05.2026 54:02
Subscribe to Biotech Blueprint for free at biotechblueprint.com In the latest joint podcast episode by Biotech Blueprint × Biotech Capital Compass, we zoom in on Moderna and where the company stands in 2026. We work through the Q1 earnings beat, the unprecedented FDA refusal-to-file on mRNA-1010, the CMV Phase 3 failure, the Vertex cystic fibrosis wind down, and the individualized neoantigen thera...
FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review – This Week in Biotech #90 20.02.2026 5:07
Subscribe to Biotech Blueprint for free at biotechblueprint.com.
Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88 06.02.2026 6:05
Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026). Follow Biotech Blueprint at biotechblueprint.com .
Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87 30.01.2026 7:13
FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026). Subscribe to Biotech Blueprint at biotechblueprint.com .
Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up 23.01.2026 7:10
This Week in Biotech #86. Subscribe to Biotech Blueprint for free at biotechblueprint.com . KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners with Janux, Corcept's overall survival win, and Corvus posts Phase 1 eczema data (Jan 16-22, 2026).
#CDC #Vaccine Schedule Shifts, Practice-Changing Phase 3 Wins, and Deal Heat – This Week in Biotech #84 09.01.2026 7:10
Subscribe to This Week in Biotech for free at biotechblueprint.com .
Inside NImmune’s Phase 3 Push in Ulcerative Colitis 10.12.2025 33:12
I sat down with NImmune CEO Josep Bassaganya-Riera to talk about omilancor, their gut-restricted oral IBD drug now in Phase 3 clinical trials. We cover LANCL2 biology, their biomarker aimed at boosting response rates, and the TITAN-X platform that helps guide real development decisions. A really interesting look at how you build an oral immunology company in 2025.Follow Biotech Blueprint for free...
FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80 10.12.2025 5:03
Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025). Subscribe to Biotech Blueprint for free at biotechblueprint.com .
CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins - This Week in Biotech #79 24.11.2025 6:05
Subscribe to Biotech Blueprint at biotechblueprint.com
FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense — This Week in Biotech #78 14.11.2025 7:32
Subscribe to Biotech Blueprint for free at biotechblueprint.com . A week of rare regulatory momentum, strategic M&A, and meaningful clinical wins.
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing 13.11.2025 51:45
Subscribe to Biotech Blueprint at biotechblueprint.com In today's episode:How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77 08.11.2025 6:58
Subscribe to Biotech Blueprint for free at biotechblueprint.com . Pfizer’s courtroom gamble to block Novo Nordisk’s $10B Metsera takeover failed, and Novo immediately fired back with an even higher bid, leaving Pfizer two days to respond before the Nov. 13 vote. Meanwhile, Trump struck landmark pricing deals with Novo and Lilly to bring GLP-1 drugs like Ozempic and Mounjaro to Medicare at $245 a m...
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76 31.10.2025 3:46
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com .
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75 26.10.2025 7:21
Subscribe to Biotech Blueprint for FREE at biotechblueprint.com .
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer 21.10.2025 51:03
Subscribe to Biotech Blueprint for free at biotechblueprint.com . About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T cells matter, and how multi-antigen mRNA vaccines aim to control reactivation. We also cover Moderna’s CMV Phase 3 (mRNA-1647) as a platform stress test and the rise of personalized neoantigen cancer va...
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74 19.10.2025 5:22
Subscribe at biotechblueprint.com .
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72 Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72 03.10.2025 5:54
Read the full edition or subscribe to Biotech Blueprint here https://www.biotechblueprint.com/p/pharma-tariffs-on-ice-fda-limits?r=474vk1
ACIP votes, Roche-89bio deal, Regeneron’s FOP win — This Week in Biotech #70 19.09.2025 8:06
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com/embed
The mRNA Revolution: Beyond COVID to Cancer, Flu and Herpes Vaccines 18.09.2025 52:02
Welcome to Biotech Blueprint. If you want to subscribe to a free weekly biotech/pharma newsletter, you can do so here: https://www.biotechblueprint.com/embed In this special episode, I teamed up again with Hartaj from the Biotech Capital Compass for part one of our mRNA therapeutics mini series. We covered the foundational science behind how RNA became medicine, the decades of bioengineering break...
Novo’s Layoffs, Novartis’ $1.4B Buy, Pancreatic Cancer Progress — This Week in Biotech #69 12.09.2025 5:29
Subscribe to Biotech Blueprint, your free biotech & pharma newsletter released every Friday at biotechblueprint.com
Ionis' Olezarsen Win, Novartis Licenses Arrowhead, CDC Vaccine Fight — This Week in Biotech #68 05.09.2025 8:10
Subscribe to Biotech Blueprint FREE weekly newsletter HERE .
Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67 29.08.2025 7:48
Subscribe to Biotech Blueprint for free HERE or at biotechblueprint.com
Viking Falls on Obesity Pill, Rocket’s Gene Therapy Resumes, FDA Greenlights Papzimeos — This Week in Biotech #66 22.08.2025 3:43
Subscribe to the Biotech Blueprint weekly newsletter for free HERE . Thanks for your support.
Lilly Bets on AI, Prasad Returns, and Brinsupri Breaks Through - This Week in Biotech #65 15.08.2025 6:08
Get the latest biotech and pharma news for free straight in your inbox. Follow Biotech Blueprint HERE .
RFK Jr. Ends mRNA Funding, Sarepta Beats Q2, and Eli Lilly Falls — This Week in Biotech #64 08.08.2025 6:59
Subscribe to Biotech Blueprint for free for weekly newsletters right in your inbox. Thanks for your support!
Similar podcasts
Listen to the Biotech Blueprint podcast in Replaio
Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.
